Terapia genica

CRISPR/Cas9 gene editing technology offers promising avenues for correcting genetic defects underlying Alzheimer’s disease. This analytical article explores the potential of CRISPR/Cas9 in developing targeted therapies, addressing challenges, and establishing ethical guidelines for its clinical application.

CRISPR/Cas9 gene editing technology holds immense promise for correcting hematologic disorders by targeting specific genetic mutations. Tuttavia, challenges remain in delivering the editing machinery efficiently and minimizing off-target effects. This article analyzes advancements and hurdles in CRISPR/Cas9-based therapies for hematologic disorders.